Ongoing Clinical Trials:

The OMEGA Study: Use of OT-551 Eye Drops to Treat Geographic Atrophy Associated With Age-Related Macular Degeneration   (Dry AMD)

PURPOSE: The purpose of this trial is to compare the ability of two doses of OT-551 ophthalmic solution and drug-free solution to safely and effectively treat geographic atrophy associated with age-related macular degeneration.

Learn more about this trial.

The National Eye Institute is evaluating Othera’s OT-551 eye drop for chronic treatment of the dry form of AMD. This single-center, open-label, study of up to 10 participants with bilateral geographic atrophy is designed to characterize the safety of 0.45% concentration of OT-551 eye drops, given 3 times a day, on participants with geographic atrophy area for up to three years.

Learn more about this trial.

Othera plans to initiate a Phase 2 clinical trial in 2008 to evaluate OT-551 in the treatment of wet AMD as an adjunctive therapy to Lucentis. Please continue to visit this website, as well as www.clinicaltrials.gov for the latest information about Othera’s clinical trials.

For more information, or if you are interested in enrolling in one of Othera's clinical trials, please contact us by e-mail at , or call (484) 879-2800.